Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Stemrim Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, creating separate prosecution paths.
VAN BUREN, LAUREN K is the busiest examiner, with 1 pending matter. Counsel can coordinate the portfolio’s biotechnology strategy while preparing examiner-specific responses for each application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017149 | COMPOSITION FOR USE IN TREATING DYSTROPHIC EPIDERMOLYSIS BULLOSA | VAN BUREN, LAUREN K | — |
| 17919872 | FORMULATION CONTAINING HMGB1 PARTIAL PEPTIDE | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18017149 | COMPOSITION FOR USE IN TREATING DYSTROPHIC EPIDERMOLYSIS BULLOSA | VAN BUREN, LAUREN K | 1638 | §112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 17919872 | FORMULATION CONTAINING HMGB1 PARTIAL PEPTIDE | BEANE, RANDALL L | 1654 | §103Other | Final Rejection | — | Pending | Oct 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStemrim Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Lauren K Van Buren has the most, with 1 of Stemrim Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
